CRISPR Therapeutics AG $CRSP Shares Sold by Amova Asset Management Americas Inc.

Amova Asset Management Americas Inc. lessened its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 10.4% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 2,163,675 shares of the company’s stock after selling 250,596 shares during the quarter. CRISPR Therapeutics makes up about 1.4% of Amova Asset Management Americas Inc.’s holdings, making the stock its 19th largest position. Amova Asset Management Americas Inc.’s holdings in CRISPR Therapeutics were worth $140,185,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in CRSP. Legal & General Group Plc raised its position in CRISPR Therapeutics by 59.7% during the second quarter. Legal & General Group Plc now owns 129,567 shares of the company’s stock worth $6,302,000 after acquiring an additional 48,412 shares during the last quarter. Philadelphia Trust Co. purchased a new position in shares of CRISPR Therapeutics during the 2nd quarter worth approximately $2,444,000. Police & Firemen s Retirement System of New Jersey acquired a new position in shares of CRISPR Therapeutics during the 2nd quarter worth approximately $911,000. JPMorgan Chase & Co. raised its position in shares of CRISPR Therapeutics by 98.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 593,416 shares of the company’s stock worth $38,459,000 after purchasing an additional 294,222 shares during the last quarter. Finally, Nwam LLC lifted its stake in CRISPR Therapeutics by 455.7% in the 3rd quarter. Nwam LLC now owns 101,769 shares of the company’s stock valued at $6,770,000 after buying an additional 83,454 shares in the last quarter. 69.20% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. Citigroup reissued a “buy” rating on shares of CRISPR Therapeutics in a report on Monday, February 16th. Royal Bank Of Canada boosted their target price on shares of CRISPR Therapeutics from $42.00 to $50.00 and gave the company a “sector perform” rating in a research note on Tuesday, November 11th. Evercore reaffirmed an “outperform” rating and set a $74.00 price target on shares of CRISPR Therapeutics in a research note on Friday, February 13th. Citizens Jmp cut their price objective on shares of CRISPR Therapeutics from $86.00 to $80.00 and set a “market outperform” rating for the company in a research report on Friday, January 30th. Finally, Robert W. Baird decreased their target price on shares of CRISPR Therapeutics from $52.00 to $44.00 and set a “neutral” rating on the stock in a research report on Tuesday, November 11th. Ten analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $64.24.

Insider Activity at CRISPR Therapeutics

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 60,000 shares of CRISPR Therapeutics stock in a transaction that occurred on Thursday, January 22nd. The shares were sold at an average price of $60.23, for a total transaction of $3,613,800.00. Following the transaction, the chief executive officer directly owned 134,201 shares of the company’s stock, valued at $8,082,926.23. The trade was a 30.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, General Counsel James R. Kasinger sold 2,112 shares of the business’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $52.58, for a total transaction of $111,048.96. Following the sale, the general counsel owned 85,115 shares of the company’s stock, valued at approximately $4,475,346.70. This represents a 2.42% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 99,079 shares of company stock worth $5,643,674 in the last 90 days. 4.30% of the stock is currently owned by insiders.

CRISPR Therapeutics Stock Up 3.3%

Shares of NASDAQ CRSP opened at $60.00 on Thursday. The stock has a market capitalization of $5.76 billion, a PE ratio of -9.20 and a beta of 1.72. The firm has a fifty day moving average of $54.20 and a 200-day moving average of $57.31. CRISPR Therapeutics AG has a 52-week low of $30.04 and a 52-week high of $78.48.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Thursday, February 12th. The company reported ($1.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.15) by ($0.22). The firm had revenue of $0.86 million for the quarter, compared to analysts’ expectations of $4.72 million. CRISPR Therapeutics had a negative net margin of 16,569.77% and a negative return on equity of 26.31%. CRISPR Therapeutics’s revenue was down 97.8% on a year-over-year basis. During the same period last year, the firm posted ($1.01) EPS. Equities research analysts expect that CRISPR Therapeutics AG will post -5.16 EPS for the current fiscal year.

About CRISPR Therapeutics

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.